-The Indian Express The SIT was set up to clear the path for justice in Gujarat. Instead, it trips on itself Ten years after the riots in Gujarat, many answers are still to be wrenched out of the system. However, the judiciary has shown its determination to ensure a thorough accounting — last month, a judgment on the Ode killings convicted 23 people. The Supreme Court, in particular, has taken extraordinary measures...
More »SEARCH RESULT
Bayer to challenge Cipla’s decision to cut price of cancer drug
-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...
More »For a universal old-age pension plan-Prabhat Patnaik
With the elderly likely to constitute a quarter of India's population by 2050, there is need for a publicly-funded, universal scheme that will overcome destitution among the aged India's social security system is woefully inadequate, when compared even to those in third world economies with no higher per capita incomes. Some States in India have fairly comprehensive social security schemes — notably Kerala, also West Bengal and Tamil Nadu — but...
More »Reaping gold through cotton, and newsprint-P Sainath
The same full page appeared twice in three years, the first time as news, the second time as an advertisement “Not a single person from the two villages has committed suicide.” Three and a half years ago, at a time when the controversy over the use of genetically modified seeds was raging across India, a newspaper story painted a heartening picture of the technology's success. “There are no suicides here and people...
More »A healthier India: Need to resolve conflict between drug price controls, innovation and affordable healthcare-David Taylor
The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...
More »